Immunovant
Ian Gourley, MD is Vice President of Clinical Development at Immunovant.
Ian is a Translational Medicine and Clinical Development physician with over 20 years of experience in the Biopharma industry. He has focused on early development of both large and small molecules in the Immunology/Inflammation space. Prior to joining Immunovant, Ian worked at CSL Behring in Clinical Pharmacology & Translational Development where he was responsible for strategy and clinical oversight of early development programs in the Immunology Therapeutic Area. Prior to CSL Behring, he held positions as Head of Translational Medicine Science, Immunology at Janssen and in Clinical Precision Medicine at Pfizer. Ian started his industry career with Eli Lilly as a Clinical Research Pathologist.
Ian received his MB, BCH and completed his MD Thesis, both from Queen’s University of Belfast, and is a Member of the Royal College of Physicians. He is a Board-Certified Clinical Pathologist and is accredited by the American Society of Histocompatibility and Immunogenetics as an HLA Laboratory Director.
This person is not in any offices
Immunovant
6 followers
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.